MedTrace Logo

Effect of Virtual Reality and Progressive Muscle Relaxation on Anxiety and Attention Among Cardiac Care Unit Patients

NCT06215066 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 158

Last updated 2025-09-26

No results posted yet for this study

Summary

A randomized controlled trial with two parallel groups was conducted, to determine the effect of virtual reality (VR) and modified progressive muscle relaxation (MPMR) distraction techniques on anxiety, attention and getting distracted from the external environment among cardiac care unit patients.

The study is based on the following hypotheses:

H1: Patients who receive VR intervention have lower Hamilton Anxiety Rating (HAM-A) scores than those who receive MPMR intervention.

H2: Patients who receive VR intervention exhibit improvement in their physiological parameters than those who receive MPMR intervention.

H3: Patients who receive VR intervention have higher Attention/Distraction scores than those who receive MPMR intervention.

Conditions

Interventions

DEVICE

Virtual reality

The VR goggles and headset phone were placed on the patient's head, straps secured, and lens spacing adjusted for a clear visual field. Patients were instructed to use head movements to control the cursor and interact with the virtual content. The 3D video clips with natural sceneries and background music were played to create a relaxing experience.

OTHER

Modified Progressive Muscle Relaxation

The exercises applied to specific body parts while patients closed their eyes and practiced deep breathing, accompanied by background music.

Sponsors & Collaborators

  • Middle East University

    collaborator OTHER

  • Alexandria University

    lead OTHER

Principal Investigators

  • Sajeda A Shdaifat, PhD-Cand · Alexandria University

  • Azza H El-Soussi, Professor · Alexandria University

  • Mohamed I Sanhoury, Asst. Prof · Alexandria University

  • Eman A Ali, Asst. Prof · Alexandria University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-20
Primary Completion
2025-05-20
Completion
2025-05-24

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06215066 on ClinicalTrials.gov